Data Readout

Vistagen's fasedienol repeat-dose trial nears a Q3 2026 SAD readout

The Phase 2 study tests whether repeat, as-needed dosing of Vistagen's intranasal fasedienol curbs acute social anxiety, following positive open-label extension data from its Phase 3 program.

By AppliedXLJuly 13, 2026Trial NCT06809179

Executive Summary

Vistagen is running a placebo-controlled Phase 2 study to see whether repeat, as-needed dosing of its intranasal fasedienol reduces acute anxiety in social anxiety disorder, a format closer to real-world use than the single-dose public-speaking challenge used in its Phase 3 program.
The company's own open-label extension data from its Phase 3 program already point to a tolerability and efficacy signal under repeat dosing, so this trial's job is to confirm that signal in a controlled design rather than establish it from scratch.
Social anxiety disorder has no other pherine-class candidate in active testing, and fasedienol is Vistagen's own most advanced program in the indication, with two Phase 3 trials running alongside this Phase 2 study.
The trial's primary completion date has already slipped four months, and its own guidance for topline data has repeated the same Q3 2026 window across five disclosures without moving, a pattern of stable, if unhurried, execution rather than one of drift or distress.

The trial

The study, registered as NCT06809179, enrolls 60 adults with social anxiety disorder to test repeat doses of fasedienol nasal spray against Placebo Nasal Spray, with the Subjective Units of Distress Scale (SUDS) as the primary endpoint and the Clinical Global Impression Scale of Improvement and Patient Global Impression of Change as secondary measures. Patients must have a clinician-rated Liebowitz Social Anxiety Scale score of at least 70 at screening, indicating severe social anxiety, and normal olfactory function, since fasedienol is delivered intranasally to act on nose-to-brain neurocircuitry. The trial remains in Recruiting status, with enrollment held flat at its original target of 60. NCT06809179

Probability of Success

Endpoint Met20%

Completes88%

Clinical Significance4%

Regulatory50%

What the drug has already shown

Vistagen disclosed preliminary data on May 12, 2026 from the open-label extension of its Phase 3 PALISADE-3 study, in which 341 patients self-administered 3.2 micrograms of fasedienol up to six times daily for as long as 12 months. Mean improvement on the 144-point LSAS scale reached 25.4 points by Month 4, with 56% of patients achieving at least a 20-point improvement, against a baseline mean score of 99.2 indicating very severe social anxiety. The discontinuation rate due to adverse events was 2.6% (9 of 341), with no discontinuations attributed to fasedienol and no drug-related serious adverse events. That result came from an open-label, uncontrolled extension; the Phase 2 study now underway is the placebo-controlled test of whether a comparable effect holds under blinded, repeat, as-needed dosing. Vistagen

Timing and stability

The trial's primary completion date moved once, from December 2025 to April 2026, a 121-day delay recorded in its registry history. Vistagen has since repeated the same Q3 2026 readout window, July 1 through September 30, across five separate disclosures dated May and June 2026, without further revision. Enrollment has not changed from its original target of 60, which the operational model treats as a routine, unremarkable pattern rather than a signal of distress. NCT06809179+1

The competitive frame

Social anxiety disorder carries no other intranasal pherine-class candidate in active testing; the closest same-drug comparators are Vistagen's own two Phase 3 trials, PALISADE-3 (NCT06358651) and PALISADE-4 (NCT06615557), both using the same SUDS primary endpoint. Other late-stage candidates in the indication, including Vanda Pharmaceuticals' VQW-765 and Newleos Therapeutics' NTX-1472, work through different, unspecified small-molecule mechanisms rather than the nose-to-brain pathway fasedienol targets. Because fasedienol has no validated same-target precedent to benchmark against, the informative outcome for this Phase 2 study is whether a repeat-dose, placebo-controlled SUDS result tracks the magnitude of improvement already seen in the open-label extension, rather than diverging back toward a placebo-like response. NCT06809179

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.